Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：10

作者：

Schipilliti, Francesca Matilde ^{[1
]}

Drittone, Denise ^{[1
]}

Mazzuca, Federica ^{[2
]}

La Forgia, Daniele ^{[3
]}

Guven, Deniz Can ^{[4
]}

Rizzo, Alessandro ^{[3
]}

机构：

[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy

[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy

[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy

[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye

来源：

HELIYON | 2024年 / 10卷 / 07期

关键词：

Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;

D O I：

10.1016/j.heliyon.2024.e28385

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.

引用

页数：7

共 50 条

[31] Immunotherapy in Triple-Negative Breast Cancer
Emens, Leisha A.
CANCER JOURNAL, 2021, 27 (01) : 59 - 66
[32] Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan
McGuinness, Julia E.
Kalinsky, Kevin
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 903 - 913
[33] Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Bartsch, Rupert
Rinnerthaler, Gabriel
Petru, Edgar
Egle, Daniel
Gnant, Michael
Balic, Marija
Sliwa, Thamer
Singer, Christian
WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 (11-12) : 347 - 361
[34] Recent advances in the treatment of triple-negative breast cancer
Pogoda, Katarzyna
Jagiello-Gruszfeld, Agnieszka
Kunkiel, Michal
Niwinska, Anna
Nowecki, Zbigniew
ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (06): : 433 - 443
[35] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A.
Hurvitz, S. A.
Tolaney, S. M.
Loirat, D.
Punie, K.
Oliveira, M.
Brufsky, A.
Sardesai, S. D.
Kalinsky, K.
Zelnak, A. B.
Weaver, R.
Traina, T.
Dalenc, F.
Aftimos, P.
Lynce, F.
Diab, S.
Cortes, J.
O'Shaughnessy, J.
Dieras, V
Ferrario, C.
Schmid, P.
Carey, L. A.
Gianni, L.
Piccart, M. J.
Loibl, S.
Goldenberg, D. M.
Hong, Q.
Olivo, M. S.
Itri, L. M.
Rugo, H. S.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) : 1529 - 1541
[36] New strategies for the management of triple-negative breast cancer
Riaz, Fauzia
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2024, 36 (01) : 40 - 44
[37] Clinical trials of immunotherapy in triple-negative breast cancer
Howard, Frederick M.
Pearson, Alexander T.
Nanda, Rita
BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (01) : 1 - 15
[38] Current state of clinical development of TROP2-directed antibody-drug conjugates for triple-negative breast cancer
Marhold, Maximilian
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (02) : 129 - 132
[39] Triple-negative breast cancers
Narod, Steven A.
Dent, Rebecca
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1041 - 1043
[40] Progress and challenges of immunotherapy in triple-negative breast cancer
Zhu, Yinxing
Zhu, Xuedan
Tang, Cuiju
Guan, Xiaoxiang
Zhang, Wenwen
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):

← 1 2 3 4 5 →